A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.
Suzuki M, Uchibori K, Oh-Hara T, Nomura Y, Suzuki R, Takemoto A, Araki M, Matsumoto S, Sagae Y, Kukimoto-Niino M, Kawase Y, Shirouzu M, Okuno Y, Nishio M, Fujita N, Katayama R.
Suzuki M, et al. Among authors: fujita n.
NPJ Precis Oncol. 2024 Feb 23;8(1):46. doi: 10.1038/s41698-024-00542-9.
NPJ Precis Oncol. 2024.
PMID: 38396251
Free PMC article.